新股消息 | 迪哲医药(688192.SH)港股IPO招股书失效

智通财经
Yesterday

智通财经APP获悉,迪哲(江苏)医药股份有限公司(简称:迪哲医药(688192.SH))于2026年1月23日所递交的港股招股书满6个月,于2026年7月23日失效,递表时高盛华泰国际为其联席保荐人。

据招股书,迪哲医药是一家处于商业化阶段的生物制药公司,公司的核心治疗领域是肿瘤及血液系统疾病。公司的上市产品舒沃哲®是全球范围内唯一获批用于治疗EGFR 20号外显子插入突变型肺癌的小分子表皮生长因子受体酪氨酸激酶抑制剂。

于2023年度、2024年度、2025年截至9月30日止九个月,该公司实现收入分别为9128.9万元、3.6亿元、5.86亿元人民币。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10